Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Rating) – Equities researchers at SVB Leerink decreased their Q2 2023 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a research note issued to investors on Tuesday, May 16th. SVB Leerink analyst D. Risinger now forecasts that the company will earn ($0.40) per share for the quarter, down from their previous forecast of ($0.39). SVB Leerink has a “Outperform” rating and a $6.00 price target on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.73) per share. SVB Leerink also issued estimates for Centessa Pharmaceuticals’ Q3 2023 earnings at ($0.39) EPS, Q4 2023 earnings at ($0.38) EPS, FY2023 earnings at ($1.71) EPS, FY2024 earnings at ($1.27) EPS, FY2025 earnings at ($1.35) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.17) EPS.
A number of other research analysts also recently commented on CNTA. Morgan Stanley dropped their target price on shares of Centessa Pharmaceuticals from $5.00 to $4.00 and set an “underweight” rating on the stock in a research report on Tuesday, January 24th. SVB Securities initiated coverage on Centessa Pharmaceuticals in a report on Friday, March 17th. They issued an “outperform” rating and a $6.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.83.
Centessa Pharmaceuticals Stock Down 5.8 %
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) last issued its earnings results on Thursday, March 30th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.03.
Institutional Investors Weigh In On Centessa Pharmaceuticals
Several hedge funds have recently modified their holdings of CNTA. BVF Inc. IL increased its position in Centessa Pharmaceuticals by 36.7% during the 1st quarter. BVF Inc. IL now owns 9,423,215 shares of the company’s stock worth $36,279,000 after purchasing an additional 2,528,870 shares during the period. EcoR1 Capital LLC raised its position in Centessa Pharmaceuticals by 7.4% in the first quarter. EcoR1 Capital LLC now owns 5,618,779 shares of the company’s stock worth $21,632,000 after acquiring an additional 386,500 shares in the last quarter. Tanager Wealth Management LLP acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $5,823,000. Woodline Partners LP boosted its position in shares of Centessa Pharmaceuticals by 10.2% during the 1st quarter. Woodline Partners LP now owns 882,633 shares of the company’s stock worth $7,917,000 after purchasing an additional 81,497 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of Centessa Pharmaceuticals by 48.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 684,127 shares of the company’s stock worth $2,634,000 after purchasing an additional 223,799 shares during the period. 78.03% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Centessa Pharmaceuticals
In other news, EVP Antoine Yver sold 6,800 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $4.42, for a total transaction of $30,056.00. Following the completion of the sale, the executive vice president now owns 789,566 shares in the company, valued at $3,489,881.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 9.09% of the stock is currently owned by company insiders.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
- Get a free copy of the StockNews.com research report on Centessa Pharmaceuticals (CNTA)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.